| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Portnoy Mark L. | Co-CEO, Director, 10%+ Owner | 700 BROOKER CREEK BLVD, SUITE 1800, OLDSMAR | /s/ Mark Portnoy | 09 Jan 2026 | 0001529249 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| holding | CCEL | Common Stock | 821,973 | 07 Jan 2026 | Direct | ||||||
| holding | CCEL | Common Stock | 42,266 | 07 Jan 2026 | By 401K | ||||||
| holding | CCEL | Common Stock | 71,529 | 07 Jan 2026 | By Partnership | F1 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | CCEL | Stock Option | Award | $194,500 | +50,000 | $3.89 | 50,000 | 07 Jan 2026 | Common Stock | 50,000 | $3.89 | Direct | F6 | |
| transaction | CCEL | Stock Option | Award | $97,250 | +25,000 | $3.89 | 25,000 | 07 Jan 2026 | Common Stock | 25,000 | $3.89 | Direct | F7 | |
| holding | CCEL | Stock Option | 22,222 | 07 Jan 2026 | Common stock | 22,222 | $7.53 | Direct | ||||||
| holding | CCEL | Stock Option | 20,000 | 07 Jan 2026 | Common Stock | 20,000 | $7.28 | Direct | ||||||
| holding | CCEL | Stock Option | 100,000 | 07 Jan 2026 | Common Stock | 100,000 | $12.27 | Direct | F2 | |||||
| holding | CCEL | Stock Option | 25,000 | 07 Jan 2026 | Common Stock | 25,000 | $4.77 | Direct | F3 | |||||
| holding | CCEL | Stock Option | 25,000 | 07 Jan 2026 | Common Stock | 25,000 | $4.30 | Direct | ||||||
| holding | CCEL | Stock Option | 25,000 | 07 Jan 2026 | Common Stock | 25,000 | $6.47 | Direct | F4 | |||||
| holding | CCEL | Stock Option | 25,000 | 07 Jan 2026 | Common Stock | 25,000 | $8.08 | Direct | F5 |
| Id | Content |
|---|---|
| F1 | Shares of common stock held by Capital Asset Fund #1 Limited Partnership, as to which Mark Portnoy may be deemed beneficial owner as its general partner. |
| F2 | Stock options will vest immediately if the price of the Company's common stock reaches $25.00 per share during the seven-year option term. |
| F3 | 8,750 stock options vest upon issuance, 8,749 options vest on 1/2/2024, 21,000 options vest on 1/2/2025 and 11,501 options vest on 1/2/2026. |
| F4 | Stock options vest 1/3 upon issuance, 1/3 on December 22, 2024 and 1/3 on December 22, 2025. |
| F5 | Stock options vest 1/3 upon issuance, 1/3 on January 21, 2026 and 1/3 on January 21, 2027. |
| F6 | The stock options were granted pursuant to the Cryo-Cell 2022 Stock Incentive Plan and an individual award agreement. The options are divided into three equal tranches, each subject to both time-based vesting and stock-price performance conditions. One tranche vests after the first anniversary of the grant date and upon the Company's common stock achieving an average closing price of at least $6 per share over 20 consecutive trading days. One tranche vests after the second anniversary and upon achieving an average closing price of at least $8 per share over 20 consecutive trading days. One tranche vests after the third anniversary and upon achieving an average closing price of at least $10 per share over 20 consecutive trading days, in each case subject to the reporting person's continued service to the Company. |
| F7 | Stock options vest 1/3 upon issuance, 1/3 on January 7, 2027 and 1/3 on January 7, 2028. |